ABBOTT PARK, Illinois, Oct. 4,
2017 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that
it has successfully completed its previously announced tender offer
to purchase for cash all outstanding shares of Series B Convertible
Perpetual Preferred Stock (the "Preferred Stock") of Alere Inc.
("Alere") at a price (the "Offer Price") of $402.00 per share of Preferred Stock, plus
accrued but unpaid dividends to, but not including, the settlement
date of the tender offer, net to the seller thereof in cash,
without interest thereon and subject to any withholding of taxes
required by applicable law (the "Offer"). The Offer was made in
connection with Abbott's previously announced agreement to acquire
Alere, which closed on Oct. 3,
2017.
The Offer expired at 11:59 p.m.
New York City time on Tuesday, Oct. 3, 2017 (the "Expiration Time").
American Stock Transfer & Trust Company, LLC, the depositary
for the Offer (the "Depositary"), has advised Abbott that as of the
Expiration Time, 1,748,025 shares of Preferred Stock had been
tendered in the Offer, representing approximately 98.5 percent of
the outstanding shares of Preferred Stock. All conditions to the
Offer having been satisfied, Abbott accepted for payment all shares
of Preferred Stock that were validly tendered and not properly
withdrawn pursuant to the Offer, and payment of the Offer Price for
such shares of Preferred Stock will be promptly made by the
Depositary.
About Abbott
Abbott is a global healthcare company
devoted to improving life through the development of products and
technologies that span the breadth of healthcare. With a portfolio
of leading, science-based offerings in diagnostics, medical
devices, nutritionals and branded generic pharmaceuticals, Abbott
serves people in more than 150 countries and employs approximately
94,000 people.
Visit Abbott at www.abbott.com and connect with us on
Twitter at @AbbottNews.
A Caution Concerning Forward-Looking Statements
Some
statements in this news release may be forward-looking statements.
Abbott cautions that these forward-looking statements are subject
to risks and uncertainties that may cause actual results to differ
materially from those indicated in the forward-looking statements.
Economic, competitive, governmental, technological and other
factors that may affect Abbott's operations are discussed in Item
1A, "Risk Factors," in Abbott's Annual Report on Form 10-K for the
year ended Dec. 31, 2016, and are
incorporated by reference. Abbott undertakes no obligation to
release publicly any revisions to forward-looking statements as a
result of subsequent events or developments, except as required by
law.
Logo -
https://mma.prnewswire.com/media/567377/Abbott_Logo.jpg